Building Quality into the Design and Conduct of Clinical Studies: Integrating Quality by Design (QbD) and Risk-Based Monitoring (RBM) Approaches Hybrid Public Meeting • National Press Club • Washington, DC January 31, 2024 | 9:00 am – 4:20 pm ET

https://healthpolicy.duke.edu/sites/default/files/2024-01/Agenda_Integrating%20Quality%20by%20Design%20and%20Risk-Based%20Monitoring%20Approaches%20Agenda_1.17.24.pdf?utm_medium=email&utm_source=govdelivery On January 31, 2024, from 9am-4:30pm EST, the U.S. Food and Drug Administration, in partnership with the Duke-Margolis Center for Health Policy, will hold a hybrid public meeting entitled "Building Quality into the Design and Conduct of Clinical Studies: Integrating Quality by Design (QbD) and Risk-Based Monitoring (RBM) Approaches." This meeting is an opportunity to facilitate a discussion among the clinical trials community and interested parties about challenges and successes of integrating QbD and RBM into the design and conduct of clinical studies. Participants may register to attend this hybrid meeting either virtually or in-person by visiting the Duke-Margolis website. https://healthpolicy.duke.edu/events/building-quality-design-and-conduct-clinical-studies-integrating-quality-design-qbd-and-risk?utm_medium=email&utm_source=govdelivery